Keytruda Crisis: Counterfeit Drugs, Insider Deals Exposed

A critical investigation has uncovered a troubling surge in counterfeit Keytruda, an essential immunotherapy drug, within India. This illicit market thrives due to limited patient access and the drug's high cost, with fake versions deceptively packaged in genuine vials, making them nearly indistinguishable. The investigation points to significant systemic failures, including regulatory gaps and compromised oversight, with evidence suggesting insider involvement in the distribution of these dangerous fakes.

Keytruda, manufactured by Merck & Co, is a leading cancer treatment that uses the body's immune system to fight tumors. Despite its effectiveness and status as the world's best-selling drug, its high price poses a significant barrier. In India, recommended doses can cost over ₹3 lakh monthly, leading many to rely on patient access programs or specialized insurance.

The investigation highlights how counterfeit drugs exploit loopholes, putting patients at severe risk. Genuine procurement from hospital pharmacies or through official patient access programs remains the most secure method to ensure one receives authentic medication. The findings underscore the urgent need for enhanced regulatory measures and stricter oversight to protect patients from counterfeit pharmaceuticals.